Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) Total Stockholders Equity : $3.57 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals Total Stockholders Equity?

Hemogenyx Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.57 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Hemogenyx Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Hemogenyx Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 1.05.

Hemogenyx Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Total Stockholders Equity Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-0.46

1.20

10.89

3.99

3.57

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial												10.89	8.52	3.99	4.63	3.57

Hemogenyx Pharmaceuticals (OTCPK:HOPHF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Hemogenyx Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.568	-	0)	/	1175.57
	=	0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Hemogenyx Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.346	+	3.384)	/	3.568
	=	1.05

Hemogenyx Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (OTCPK:HOPHF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

HEMO:UK 5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.